Is Monte Rosa Therapeutics, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Monte Rosa Therapeutics, Inc. has moved from very attractive to fair. Based on the current metrics, the company appears to be fairly valued. The P/E ratio stands at 50, while the Price to Book Value is 1.12, and the PEG Ratio is 0.48, indicating that the stock may not be significantly undervalued despite its previous attractive rating.
In comparison with peers, Monte Rosa's P/E ratio of 12.27 is notably higher than MeiraGTx Holdings Plc, which has a P/E of -3.82, and 23andMe Holding Co., which has a P/E of -0.75, suggesting that Monte Rosa is relatively more valued in the market. Over the past year, Monte Rosa has delivered a return of 83.06%, significantly outperforming the S&P 500's return of 14.08%, reinforcing the notion that the stock is currently fairly valued in light of its recent performance.